Real World Evidence Conference

This conference has reached maximum capacity.

戻る Agenda

Session 5: Use of RWE in Label Expansion

Session Chair(s)

Paul M. Coplan, DrSc, MBA, MSc, FISPE

VP, Medical Device Epidemiology & Real-World Data Analytics

Johnson & Johnson, United States

Marni Hall, PhD, MPH

Vice President and General Manager, Global Regulatory Science and Strategy

IQVIA, United States

21st Century Cures Act and the current user fee commitments direct and give FDA the authority to develop a framework for use of real world evidence for indication expansion. This section will discuss the current landscape, examples of when RWE protocols have been accepted by FDA for label expansion, and strategies for more broad application, including the criteria for routine use.

Learning Objective : At the conclusion of this session, participants should be able to:
Describe three criteria in which RWE has been used for label expansion
Explain why it will be necessary to employ different assessments for different therapeutic areas
Propose one or more pilot projects to advance a framework for use of RWE for label expansion

Speaker(s)

Use of Real World Evidence to Expand Labels: Expectations, Opportunities, and Challenges

Peter P. Stein, MD

FDA, United States

Director, Office of New Drugs, CDER

Use of RWE in Label Expansion

Nancy A Dreyer, PhD, MPH, FISPE

Dreyer Strategies LLC, United States

Founder